Presented by: Aditi Sakpal
MBA PM-15 (0561)

EVOLVING DYNAMICS OF MARKETING, SALES, AND SUPPLY CHAIN IN THE INDIAN PHARMACEUTICAL INDUSTRY:TRENDS, CHALLENGES, AND OPPORTUNITIES

Industry Mentor: Mr. Rahul Thosar
University Mentor: Dr. Rahul Sharma

Abstract

India's pharma industry, known for affordable generics and exports, is undergoing major change due to global supply disruptions, regulatory reforms, and digital healthcare trends. This study examines shifts in marketing, sales, and supply chain strategies in response to these challenges.

Key findings show a move from traditional marketing to AI-driven, omnichannel engagement; rising use of DTC and e-pharmacies; and improved supply chains through local API production, blockchain, and IoT. Reforms like UCPMP 2024 and the PLI scheme are driving ethical and operational changes.

To stay competitive, firms must embrace technology, follow regulations, and adopt patient-focused, data-driven models.

Introduction

The Indian pharmaceutical sector, the world's largest supplier of generic medicines, is vital to global healthcare and India's economy. With over 10,500 manufacturing units, it is known for cost-effective, quality production. Expected to grow from USD 50 billion in 2023 to over USD 130 billion by 2030, the industry faces challenges like regulatory changes, pricing pressures, and supply chain disruptions. Marketing, sales, and supply chain functions are evolving—shifting to digital, omnichannel, and tech-driven models to enhance compliance, efficiency, and patient engagement.

What is Ethical Marketing in Pharma?

In the pharmaceutical sector, ethical marketing is the practice of promoting medications and health products in a way that is truthful, accurate from a scientific standpoint, socially conscious, and complies with national and international laws.

- Regulatory Compliance and Truthful Promotion
- Transparency and Responsible Engagement
- Building Trust through Ethical Practices

SWOT ANALYSIS

Indian Pharmaceutical Market

S

Strengths

- Global Generic Leader
- Strong Manufacturing Base
- Skilled Talent and R&D
- Low-cost Production

W

Weaknesses

- API Import Dependence
- Regulatory Compliance Gaps
- Fragmented Market
- Low Drug Innovation

O

Opportunities

- Digital & E-Pharma Growth
- PLI Scheme Support
- Global Demand for Generics
- Biosimilars Boom

T

Threats

- Price Controls (NLEM)
- Geopolitical/API Supply
- Rising Global Competition
- Export Market Scrutiny

LITERATURE REVIEW

Evolution of Pharma Marketing

The Indian pharmaceutical industry, known as the "Pharmacy of the World," began with Bengal Chemicals in 1901. After independence, the 1970 Indian Patent Act allowed only process patents, enabling local firms to reverse-engineer drugs and adopt more competitive marketing, boosting domestic growth.

In the 1970s–80s, marketing was product-focused and reliant on medical representatives. In the 1990s, competition and global exposure brought structured strategies like segmentation, branding, and modern promotions. Branded generics later emphasized differentiation using KOLs, scientific communication, and CME.

Recently, digital platforms, AI, and CRM tools have transformed marketing toward patient-centric and value-based approaches. These evolving strategies, combined with cost-effective manufacturing, have cemented India's position as a major global pharmaceutical hub.

Marketing

AI & Big Data

- AI personalizes content and automates delivery.
- Big Data targets patient groups and predicts needs.

Traditional vs. Digital

- Traditional: Print, reps, events — builds trust but costly, less measurable.
- Digital: Websites, email, social media — targeted, flexible, cost-effective.

UCPMP 2024 Impact

- Stricter rules on gifts, samples, and HCP interactions.
- Mandatory disclosures and CEO accountability.
- Promotes ethical, transparent pharma marketing.

Sales Strategies

Indian pharma sales are shifting to hybrid, data-driven models, blending digital tools with in-person engagement. The focus is now on value-based, personalized interactions. AI and real-time data enhance targeting and salesforce efficiency, while UCPMP 2024 enforces ethical, transparent practices. This digital-ethical approach is key to future growth.

E-pharmacies now play a key role in India's pharma sector, offering round-the-clock access and convenience. Pharma firms use omnichannel strategies, guided by UCPMP 2024 for ethical digital promotion.

DTC connects pharma to patients via apps, using AI for personalized engagement. UCPMP 2024 ensures transparency, boosting access and loyalty.

Hospitals use value-based, tech-driven procurement supported by CRM, AI, and analytics. GPOs require bundled services and supply resilience, with ethics and UCPMP 2024 compliance crucial.

Supply Chain Management

The pharmaceutical supply chain is shifting from a cost-centric to a tech-enabled, resilient model. COVID-19 exposed major gaps, prompting focus on diversification, risk management, and real-time visibility. Trends like AI forecasting, blockchain, green logistics, and automation are transforming the landscape

API Dependence on China

India imports 65–70% of APIs from China. PLI schemes and tech adoption aim to boost local production and reduce reliance.

Cold Chain Technologies

The 2024 PLI Scheme boosts local API production. Bulk Drug Parks cut costs, while UCPMP reforms and digital tools support pharma self-reliance.

Government Schemes

The 2024 PLI Scheme promotes local API production. Bulk Drug Parks cut costs, and UCPMP reforms with digital push support pharma self-reliance

Regulatory and Policy Landscape

Price Control Measures

NPPA caps drug and device prices to stabilize costs but risks limiting innovation. It's adopting digital tools for better oversight

GST Impact

GST unified taxes in 2017, cutting costs and improving logistics, tracking, and access to medicines

India's pharma sector is driven by reforms promoting ethics, affordability, innovation, and supply chain resilience. UCPMP 2024 enforces ethical marketing aligned with global standards. NPPA caps prices and supports innovation via PLI. WHO encourages harmonization and stricter ethics, while new laws focus on quality, risk, and export traceability, creating a transparent, ethical, and innovative environment.

Technological Disruptions

AI IN SALES & ENGAGEMENT

AI is transforming pharma sales through accurate forecasting and optimized resource planning. It enhances HCP engagement via real-time personalization and supports hybrid marketing with AI-driven targeting. Chatbots, virtual assistants, and NLP tools improve customer support and digital strategy.

IOT & BLOCKCHAIN

IoT devices track pharma shipments in real time to ensure GDP compliance. Blockchain provides secure, tamper-proof tracking to prevent counterfeits and ensure traceability. As adoption grows, these tools enhance audit trails, ERP integration, and regulatory compliance.

Research Methodology

This study uses secondary research, analyzing existing data from reliable sources to explore trends in pharmaceutical marketing, sales, and supply chains in India. It enables a broad, time-efficient analysis of industry developments without the constraints of primary data collection.

Data Sources

- **Government Reports:** MoHFW, NPPA, DoP, CDSCO.
- **Industry Bodies:** IPA, OPPI, IDMA, FICCI.
- **Academic Journals:** PubMed, Scopus, Google Scholar.
- **Market Intelligence:** IQVIA, McKinsey, Deloitte, EY.
- **Company Reports:** Sun Pharma, Dr. Reddy's, Cipla.
- **Media & Trade Magazines:** Economic Times, Pharma Times.

Justification for Secondary Research

- **Data Availability:** Abundant public data from government, industry, and academic sources.
- **Cost & Time Efficient:** Avoids resource-heavy surveys or interviews.
- **Ethical Ease:** No need for permissions or confidential disclosures.
- **Broader Insight:** Captures large-scale trends like digital transformation and policy shifts.

Data Analysis and Findings

Over the past decade, the Indian pharmaceutical industry has undergone significant transformation driven by digitalization, policy reforms, and changing market dynamics.

Marketing Evolution

2015–2017

- Focused on field force visits, print materials, CME sponsorships.
- ROI limited due to high competition and generic saturation.

2018–2020

Early digital efforts began—WhatsApp updates, basic HCP portals, social media content

2021–2025

- KPIs now focus on prescription impact, not visit count.
- SFA tools like Veeva boost efficiency.
- Hybrid selling blends digital and in-person.
- Dashboards enable real-time performance tracking

Sales Force Transformation

KPI Shift: From visit frequency to outcomes like prescription lift and engagement quality

Sales Force Automation (SFA): Adoption of Veeva CRM and mobile tools improved productivity

Hybrid Selling Models: Post-COVID, sales reps use both digital and in-person interactions

Data-Driven Performance: Real-time dashboards monitor MR activity, HCP responses, and sales target alignment



Supply Chain Management (SCM) Advancements

2015-2017

Manual, ledger-based operations; push-model dependent on distributors

2018-2020

Introduction of ERP systems (SAP HANA), barcode tracking, and warehouse management systems (WMS)

2021-2025

- IoT tracks cold chain for biologics.
- AI predicts restocking to avoid stockouts.
- E-invoicing & GST automation streamline ops.
- Drones enhance rural medicine delivery

- Indian pharma is rapidly moving from traditional, manual practices to data-driven, tech-integrated operations.
- Digital and omnichannel strategies are reshaping HCP engagement and patient outreach.
- SCM is shifting from reactive to predictive and transparent, aligning with global efficiency standards.

Key Trends in IPM

01 **Digital Marketing Transformation:** Shift from field force to AI-powered omnichannel engagement (CRM, webinars, e-detailing)

02 **Rise of E-Pharmacies & DTC Models:** Platforms like 1mg and PharmEasy enabling direct patient access and personalized care

03 **Technological Integration:** Adoption of AI, IoT, blockchain, and big data across marketing, sales, and supply chains

04

Ethical Marketing Focus: Enforcement of UCPMP 2024 promoting compliance and transparency in HCP engagement

05

Supply Chain Resilience: PLI scheme and bulk drug parks reducing API dependence; real-time logistics via cold chain tech

Major Challenges

API Dependency: Over 65% of APIs imported from China; vulnerable to geopolitical and supply shocks

Regulatory Compliance Pressure: Increasing scrutiny from NPPA, UCPMP, and global agencies like USFDA

Digital Divide: Uneven digital adoption, especially in rural areas and Tier 3 cities

Data Privacy Concerns: Compliance with the Digital Personal Data Protection Act (2023) adds complexity to digital engagement

Price Controls: NPPA price ceilings on essential medicines impact margins and innovation incentives

Emerging Opportunities

01 **PLI Scheme & Bulk Drug Parks:** Incentives for domestic API and medical device manufacturing

02 **Biosimilars & Biotech Growth:** Patent expirations create room for India to lead in complex generics and biosimilars

03 **DTC & Telehealth Boom:** Increasing health awareness and tech use expanding direct access and patient-centric models

04 **Green Logistics & ESG Focus:** Growing emphasis on sustainable supply chain practices and digital traceability.

Conclusion

The Indian pharmaceutical sector stands at a pivotal point, with strong growth potential and major transformative challenges. This research highlights the need for:

- A digital-first approach across commercial functions
- Ethical, regulation-compliant marketing
- Customer-driven, insight-based sales strategies
- Tech-enabled, localized, and resilient supply chains

As the industry becomes more patient-centric, embracing transparency, innovation, and agility will be key to maintaining global leadership. Success will depend on adaptability, collaboration, and sustainable practices that align profitability with public health impact.

THANK YOU!